Biotech Values

[caravon]

Rather, this is simply an agreement to conduct a phase-2 trial of two unapproved drugs

CLVS likes to do few things:
- The management is not looking for partners at this time
- CLVS wants to get access to Genentech's immune-technology pipeline to broaden its own oncology utilities without compromising its own Roci development.
- At this junction, Genentech will provide CLVS with its drug before it is potentially approved by FDA getting Genentech proprietary info.
- A drug development partnership will require financing arrangements, therefore, imposing some degree of development coordination. This in turn would impose limitations on CLVS's Roci development strategy and implementation. The present arrangement will free CLVS from any Roche interference in Roci development.

This is why CLVS has had its secondary just recently.